pharma · cystic fibrosis · Relapsing Multiple Sclerosis (relapsing-remitting, relapsing-progressive)
Théa Pharma Ireland
Verona Pharma Ireland Limited
Théa Pharma Ireland trial registry — 11 ClinicalTrials.gov studies with program phase, status, and indication context.
Castlebar, IE HQ
2018 Founded
19 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Castlebar, IE
- Founded
- 2018
- Employees
- 19
- Programs
- 11
- Drugs
- 42
- Patents
- 0
Théa Pharma Ireland clinical trials
Registry index of 11 ClinicalTrials.gov studies linked to Théa Pharma Ireland programs — each row shows trial ID, program name, phase, status, and indication.
Théa Pharma Ireland trial registry — 11 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Théa Pharma Ireland.
-
PASSION — Phase 2
Clinical update -
GR-2021-12373041 — Approved
Clinical update -
CRCFC-TEICO.SA.2022 — Phase 2
Clinical update -
SIPO20 — Approved
Clinical update -
SAVE PAIN 2025 — Phase 3
Clinical update -
PIPAC_VEROne — Phase 3
Clinical update -
INCIPIT — Phase 2
Clinical update -
DISCARD — Approved
Clinical update
Trial registry
-
CTIS ↗ -
CTIS ↗ -
CTIS ↗ -
CTIS ↗ - 2024-517820-21-00CTIS ↗
CRCFC-TEICO.SA.2022
cystic fibrosis associated to persistent Staphylococcus aureus (including MRSA) infection
- 2024-518374-13-00CTIS ↗
SIPO20
Active progressive multiple sclerosis course after an initial relapse clinical course
-
CTIS ↗ - 2024-518859-27-00CTIS ↗
Zeposia 0.92 mg hard capsules
Relapsing Multiple Sclerosis (relapsing-remitting, relapsing-progressive)
-
CTIS ↗ -
CTIS ↗ - 2025-522530-31-01CTIS ↗
PASSION
Patients with metastatic PDAC, who have not progressed following completion of at least 16 weeks (can be more) of any multiagent first-line chemotherapy